Erratum zu diesem Artikel: Erratum Gesundheitswesen 2007; 69(05): 324-324
DOI: 10.1055/s-2007-985817
Zusammenfassung
Am 5. Oktober 2006 veranstaltete das Nationale Referenzzentrum für Meningokokken (NRZM)
in Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM)
den 3. Workshop zur Epidemiologie, Prävention und Therapie der invasiven Meningokokkenerkrankung.
Anlässlich der neuen, im August 2006 von der Ständigen Impfkomission (STIKO) ausgesprochenen
Empfehlung für eine Impfung gegen Meningokokken der Serogruppe C für alle Kinder im
zweiten Lebensjahr wurden Erfahrungen aus unterschiedlichen Impfkampagnen europäischer
Länder vorgestellt und mit der deutschen Situation verglichen. Die Tagung bot die
Möglichkeit, am NRZM genützte computergestützte Clustererkennungsmethoden, sowie deren
Integration in das interaktive Geografische Informationssystem EpiScanGIS kennen zu
lernen. Interventionsmöglichkeiten von öffentlichen Gesundheitsbehörden wurden anhand
regionaler Inzidenzerhöhungen in Oberallgäu, Sangerhausen und im Großraum Aachen veranschaulicht.
Überdies wurden gegenwärtige Entwicklungen aus der Meningokokkenforschung und die
Resistenzentwicklung auf europäischer Ebene beleuchtet, sowie die aktuelle Evidenzlage
bezüglich des klinischen Managements und der Chemoprophylaxe dieser invasiven bakteriellen
Erkrankung präsentiert.
Abstract
On October 5th, 2006, the German Reference Centre for Meningococci (NRZM) held the
3rd Workshop on Epidemiology, Prevention and Treatment of Invasive Meningococcal Disease,
in collaboration with the German Society for Hygiene and Microbiology (DGHM). Given
the recent recommendation of the German Standing Committee on Vaccination (STIKO)
for conjugate meningococcal C vaccination of all children in the second year of life,
observations from meningococcal C conjugate vaccination campaigns in other European
countries were presented and compared to the German situation. Moreover, the newly
implemented cluster detection routines employed at the NRZM and their integration
into the interactive geographical information system EpiScanGIS were shown. Based
on recent experiences from regional outbreaks in Oberallgäu, Sangerhausen, and Greater
Aachen, examples for public health intervention were given at the conference. In addition,
current developments in the area of meningococcal research, as well as trends in antimicrobial
susceptibility were covered. Finally, the latest evidence concerning the clinical
management and chemoprophylaxis of this invasive bacterial disease was discussed.
Schlüsselwörter
invasive Meningokokken-erkrankung - Sepsis - Meningitis
Key words
Invasive Meningococcal disease - sepsis - meningitis
Literatur
1
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E.
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database
analysis.
Bmj.
2003;
326
365-366
2
Trotter CL, Edmunds WJ.
Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines
using a transmission dynamic model.
Med Decis Making.
2006;
26
38-47
3
Schrauder A, Claus H, Elias J. et al .
Capture-recapture analysis to estimate the incidence of invasive meningococcal disease
in Germany, 2003.
Epidemiol Infect.
2006;
1-8
4
Giuliani MM, Adu-Bobie J, Comanducci M. et al .
A universal vaccine for serogroup B meningococcus.
Proc Natl Acad Sci USA.
2006;
103
10834-10839
5
Bille E, Zahar JR, Perrin A. et al .
A chromosomally integrated bacteriophage in invasive meningococci.
J Exp Med.
2005;
201
1905-1913
6
Pearson N, Gunnell DJ, Dunn C. et al .
Antibiotic prophylaxis for bacterial meningitis: overuse and uncertain efficacy.
J Public Health Med.
1995;
17
455-458
7
Hastings L, Stuart J, Andrews N, Begg N.
A retrospective survey of clusters of meningococcal disease in England and Wales,
1993 to 1995: estimated risks of further cases in household and educational settings.
Commun Dis Rep CDR Rev.
1997;
7
R195-R200
8
Purcell B, Samuelsson S, Hahne SJ. et al .
Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic
review.
Bmj.
2004;
328
1339
9
Fraser A, Gafter-Gvili A, Paul M, Leibovici L.
Antibiotics for preventing meningococcal infections.
Cochrane Database Syst Rev.
2006;
CD004785
10
Girgis N, Sultan Y, Frenck Jr RW. et al .
Azithromycin compared with rifampin for eradication of nasopharyngeal colonization
by Neisseria meningitidis.
Pediatr Infect Dis J.
1998;
17
816-819
11
Boccia D, Andrews N, Samuelsson S. et al .
Effectiveness of different policies in preventing meningococcal disease clusters following
a single case in day-care and pre-school settings in Europe.
Epidemiol Infect.
2006;
134
872-877
12
Kulldorff M.
A spatial scan statistic.
Communications in Statistics: Theory and Methods.
1997;
26
1481-1496
13
Mostashari F, Kulldorff M, Hartman JJ, Miller JR, Kulasekera V.
Dead bird clusters as an early warning system for West Nile virus activity.
Emerg Infect Dis.
2003;
9
641-646
14
Cousens S, Smith PG, Ward H. et al .
Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000.
Lancet.
2001;
357
1002-1007
15
Sauders BD, Fortes ED, Morse DL. et al .
Molecular subtyping to detect human listeriosis clusters.
Emerg Infect Dis.
2003;
9
672-680
16
Chaput EK, Meek JI, Heimer R.
Spatial analysis of human granulocytic ehrlichiosis near Lyme, Connecticut.
Emerg Infect Dis.
2002;
8
943-948
17
Elias J, Harmsen D, Claus H. et al .
Spatio-temporal analysis of invasive meningococcal disease, Germany.
Emerg Infect Dis.
2006;
12
1689-1694
18
Elias J, Claus H, Frosch M, Vogel U. Health Office in the Rural District Office Wartburgkreis
.
Evidence for indirect nosocomial transmission of Neisseria meningitidis resulting
in two cases of invasive meningococcal disease.
J Clin Microbiol.
2006;
44
4276-4278
19 Snow J. On the mode of transmission of cholera. In: WH Frost (Ed) Snow on cholera
(2nd ed) New York: The Commonwealth Fund 1936
20
Rolfhamre P, Janson A, Arneborn M, Ekdahl K.
SmiNet-2: Description of an internet-based surveillance system for communicable diseases
in Sweden.
Euro Surveill.
2006;
11
103-107
21
Shuai J, Buck P, Sockett P, Aramini J, Pollari F.
A GIS-driven integrated real-time surveillance pilot system for national West Nile
virus dead bird surveillance in Canada.
Int J Health Geogr.
2006;
5
17
22
Hautmann W, Harms I, Vogel U, Zirngibl A, Wildner M.
Cluster of meningococcal diseases in Allgaeu - strategies for intervention].
Gesundheitswesen.
2005;
67
853-857
23
Oppermann H, Thriene B, Irmscher HM. et al .
[Meningococcal carriage in high school students and possible risk factors].
Gesundheitswesen.
2006;
68
633-637
24
Schröter M, Elias J, Hellenbrand W. et al .
Die Epidemiologie von Neisseria meningitidis in NRW.
Rheinisches Ärzteblatt.
2006;
4
19-21
25
Cano R, Larrauri A, Mateo S. et al .
Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological
decision.
Euro Surveill.
2004;
9
11-15
26
de Greeff SC, de Melker HE, Spanjaard L, van den Hof S, Dankert J.
[The first effect of the national vaccination campaign against meningococcal-C disease:
a rapid and sharp decrease in the number of patients].
Ned Tijdschr Geneeskd.
2003;
147
1132-1135
27
de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A.
Protection from routine vaccination at the age of 14 months with meningococcal serogroup
C conjugate vaccine in the Netherlands.
Pediatr Infect Dis J.
2006;
25
79-80
28
Martin DR, Walker SJ, Baker MG, Lennon DR.
New Zealand epidemic of meningococcal disease identified by a strain with phenotype
B:4:P1.4.
J Infect Dis.
1998;
177
497-500
29
Arreaza L, Salcedo C, Alcala B. et al .
Sequencing of Neisseria meningitidis penA gene: the key to success in defining penicillin
G breakpoints.
Antimicrob Agents Chemother.
2004;
48
358-359
30
Antignac A, Ducos-Galand M, Guiyoule A. et al .
Neisseria meningitidis strains isolated from invasive infections in France (1999-2002):
phenotypes and antibiotic susceptibility patterns.
Clin Infect Dis.
2003;
37
912-920
31
Taha MK, Zarantonelli ML, Ruckly C, Giorgini D, Alonso JM.
Rifampin-resistant Neisseria meningitidis.
Emerg Infect Dis.
2006;
12
859-860
32
Zenz W, Zoehrer B, Levin M. et al .
Use of recombinant tissue plasminogen activator in children with meningococcal purpura
fulminans: a retrospective study.
Crit Care Med.
2004;
32
1777-1780
33
Alberio L, Lammle B, Esmon CT.
Protein C replacement in severe meningococcemia: rationale and clinical experience.
Clin Infect Dis.
2001;
32
1338-1346
34
Vincent JL, Nadel S, Kutsogiannis DJ. et al .
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura
fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients
enrolled in recent clinical studies.
Crit Care.
2005;
9
R331-R343
35
Casella EB, Cypel S, Osmo AA. et al .
Sequelae from meningococcal meningitis in children: a critical analysis of dexamethasone
therapy.
Arq Neuropsiquiatr.
2004;
62
421-428
36
Kurzai O, Schmitt C, Claus H. et al .
Carbohydrate composition of meningococcal lipopolysaccharide modulates the interaction
of Neisseria meningitidis with human dendritic cells.
Cell Microbiol.
2005;
7
1319-1334
37
Yazdankhah SP, Kriz P, Tzanakaki G. et al .
Distribution of serogroups and genotypes among disease-associated and carried isolates
of Neisseria meningitidis from the Czech Republic, Greece, and Norway.
J Clin Microbiol.
2004;
42
5146-5153
38
Smirnova I, Mann N, Dols A. et al .
Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations
in meningococcal susceptibility.
Proc Natl Acad Sci USA.
2003;
100
6075-6080
39
Emonts M, Hazelzet JA, de Groot R, Hermans PW.
Host genetic determinants of Neisseria meningitidis infections.
Lancet Infect Dis.
2003;
3
565-577
40
Zangwill KM, Schuchat A, Riedo FX. et al .
School-based clusters of meningococcal disease in the United States. Descriptive epidemiology
and a case-control analysis.
Jama.
1997;
277
389-395
41
Davison KL, Andrews N, White JM. et al .
Clusters of meningococcal disease in school and preschool settings in England and
Wales: what is the risk?.
Arch Dis Child.
2004;
89
256-260
42
Gilmore A, Stuart J, Andrews N.
Risk of secondary meningococcal disease in health-care workers.
Lancet.
2000;
356
1654-1655
Korrespondenzadresse
Dr. med. univ. J. Elias
Institut für Hygiene und Mikrobiologie
Universität Würzburg
Josef-Schneider-Straße 2
Bau E1 97080 Würzburg
eMail: jelias@hygiene.uni-wuerzburg.de
Prof. Dr. med. U. Vogel
Institut für Hygiene und Mikrobiologie
Universität Würzburg
Josef-Schneider-Straße 2
Bau E1 97080 Würzburg
eMail: uvogel@hygiene.uni-wuerzburg.de